July 2 (Reuters) - Cartesian Therapeutics said on Tuesday that its experimental autoimmune disorder therapy met the main goal of a mid-stage trial. (Reporting by Sneha S K in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.62 USD | +11.73% | -28.81% | -14.81% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.81% | 314M | |
+15.58% | 121B | |
+16.60% | 110B | |
+18.17% | 25.93B | |
-24.33% | 19.27B | |
-19.28% | 16.01B | |
-17.95% | 15.66B | |
-46.81% | 14.89B | |
+58.78% | 14.47B | |
+4.91% | 13.91B |
- Stock Market
- Equities
- RNAC Stock
- News Cartesian Therapeutics, Inc.
- Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study